Search Results

You are looking at 41 - 50 of 91 items for :

  • "cytoreduction" x
  • Refine by Access: All x
Clear All
Full access

Updates in the Management of Myelofibrosis

Presented by: Andrew T. Kuykendall

cytoreduction. “What’s worth noting in patients with a lower risk is that clinical trials are really the preferred approach, because this is a group and a disease in which we feel we need to do better in terms of the treatments offered,” said Dr. Kuykendall

Full access

Patient Case Studies and Panel Discussion: Leukemia – Rare and Emerging Subtypes

apheresis for CAR-T generation, and experienced favorable cytoreduction (she received fludarabine/cyclophosphamide for lymphodepletion). She then received a post–CAR-T infusion and showed no response; her blast count increased from 0.42 to 80.35 within a

Full access

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

recommendations for R/R classic HL and high-light important updates with relevant supporting data. Updates to the Treatment of R/R Classic HL Second-Line and Subsequent Systemic Therapy Several studies have shown the importance of cytoreduction with

Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

E . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer . J Clin Oncol 2003 ; 21 : 3737 – 3743

Full access

Liver-Directed Therapies in Patients With Advanced Neuroendocrine Tumors

Natalie B. Jones, Manisha H. Shah, and Mark Bloomston

, particularly when undertaken with curative intent (median, 50 vs. 32 months for cytoreduction and 24 months for embolization). Several retrospective series have sought to characterize prognostic factors that may help in patient selection for resection of

Full access

Soft Tissue Sarcoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Margaret von Mehren, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Sridhar Shankar, Brian A. Van Tine, Jeffrey Wayne, Hema Sundar, and Nicole R. McMillian

patients) reported a response rate of 70% after 3 to 7 days of preoperative imatinib (600 mg/d) in patients undergoing surgical resection for primary or recurrent GISTs. 13 However, results showed no histologic evidence of cytoreduction within 3 to 7 days

Full access

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson

combination with primary surgery when feasible. This strategy allows cytoreduction with chemotherapy followed by potentially curative surgery in settings where RT is not typically available. These alternative treatment modalities represent elemental steps that

Full access

Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post–JAK2 V617F Discovery Era

Elizabeth M. Kander, Alison R. Moliterno, Alfred Rademaker, Michael B. Streiff, Jerry L. Spivak, and Brady L. Stein

common indications for cytoreduction. Almost half of respondents believed thrombocytosis was an indication for cytoreductive therapy (43.7%); 50.8% of respondents prescribed hydroxyurea regardless of age, whereas 32.8% avoided its use in patients younger

Full access

Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant

Jeffrey E. Lancet and Sergio Giralt

with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases . Blood 1998 ; 91 : 756 – 763 . 56. Khouri I Keating MJ Korbling M . Transplant lite: induction of graft vs malignancy using fludarabine based

Full access

Adult Intradural Primary Spinal Cord Tumors

Kamran Aghayev, Frank Vrionis, and Marc C. Chamberlain

corresponding prognosis, and removes bulk tumor (i.e., cytoreduction). In most well-defined (circumscribed) low-grade tumors, resective surgery can be curative. With infiltrative tumors, maximal safe resection or biopsy helps provide a diagnosis and define